Tablets "Norkolut®" are used for secondary amenorrhea, endometriosis.
Active ingredient: norethisterone; 17α-ethynyl-17β-hydroxy-4-estren-3-one (one tablet contains 5 mg norethisterone).
Excipients: potato starch, magnesium stearate, anhydrous colloidal silicon dioxide, gelatin, talc, corn starch, lactose monohydrate.
Do not use the preparation "Norkolut®" in the presence of any of the conditions or diseases listed below:
Tablets should be taken whole with liquid, without chewing.
The effectiveness of Norkolut® tablets may be reduced if the patient forgets to take the tablet as directed. The patient should only take the last missed tablet as soon as she remembers, and then continue taking the tablets at the usual time the next day.
If contraceptives are necessary, then non-hormonal methods of contraception should be used additionally.
Secondary amenorrhea
Any hormonal therapy for secondary amenorrhea can only be given after pregnancy has been ruled out. In some cases, secondary amenorrhea is due to prolactinoma, which should be excluded before starting the use of Norkolut®.
The doctor prescribes a preparation containing estrogen (for example, within 14 days) before the use of the preparation "Norcolut®" is started. After that, take one tablet of Norkolut® 1-2 times a day for 10 days. Withdrawal bleeding begins a few days after taking the last pill.
When a sufficient level of estrogen production is reached, you can try to stop estrogen therapy and induce cyclic bleeding with one tablet of the preparation "Norcolut®" 2 times a day from the 16th to the 25th day of the cycle.
endometriosis
Treatment should be started between the first and fifth day of the cycle with the use of one tablet of Norkolut® twice a day. In the event of spotting, it is necessary to increase the dose and take two tablets of Norkolut® twice a day. After the bleeding stops, you can reduce the dose to the initial one. The duration of the course of treatment is at least 4-6 months. With continuous daily use of the preparation, ovulation and menstruation are absent. Withdrawal bleeding occurs after hormone therapy is completed.
Children
The preparation should not be used in children.
Drivers
The effect on the ability to drive a car or work with mechanisms did not differ.
Acute toxicity studies have not demonstrated the risk of acute adverse reactions in case of accidental administration of the preparation at a dose that is several times higher than the daily therapeutic dose.
Side effects often occur in the first months after the start of taking Norkolut®.
Such adverse events have been reported in patients taking norethisterone, although a causal relationship could not always be confirmed.
From the reproductive system and mammary glands: very frequent (≥ 1/10) - uterine / vaginal bleeding, including spotting; hypomenorrhea.
Store at a temperature not exceeding 30 ° C, out of the reach of children.
Shelf life - 5 years.
There are no reviews for this product.